Here are four things to know.
1. Zinbryta, which treats about 3,000 patients worldwide, was approved by the FDA in 2016 with a boxed warning due to liver damage risks.
2. Biogen sold the drug in Switzerland, Canada and the European Union. AbbVie marketed the drug in the U.S.
3. The drugmakers’ decision to withdraw the drug from the market is a result of eight cases of encephalitis, or inflammation of the brain, and meningoencephalitis, which simultaneously resembles meningitis and encephalitis. The cases were reported in Germany and Spain.
4. The European Medicines Agency launched an urgent review into the product.
More articles on supply chain:
Teva shutters offices in New York City, Washington D.C., as part of cost cutting plan
Walgreens, AmerisourceBergen reportedly end takeover discussions with no deal
3 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.